CAS: 123606-06-4

Riamilovir is an antiviral agent, which is synthesized chemically, designed to combat the replication of specific viruses. It acts as a nucleoside analogue, interfering with viral nucleic acid synthesis. By incorporating itself into the viral RNA, it effectively hampers the ability of the virus to replicate its genetic material, thereby inhibiting its proliferation within the host. Riamilovir is predominantly used in the treatment of infections caused by the influenza virus. Its application extends to clinical settings where rapid virus replication poses a significant threat to patient health. Researchers are also exploring its potential usefulness against other RNA viruses due to its mechanism targeting viral replication. The mode of action provides a critical tool in virology, offering insights into virus dynamics and assisting in the development of broad-spectrum antiviral therapies. This compound is pivotal in informing strategies for controlling outbreaks and managing antiviral resistance.

Riamilovir (7-methylsulfanyl-3-nitro-6H-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-one) is a broad-spectrum antiviral drug candidate.

Riamilovir